Cellular Activation of the Self-Quenched Fluorescent Reporter Probe in Tumor Microenvironment  by Bogdanov, Alexei A. et al.
Cellular Activation of the Self-Quenched Fluorescent Reporter
Probe in Tumor Microenvironment
Alexei A. Bogdanov Jr. *, Charles P. Lin y, Maria Simonova *, Lars Matuszewski * and Ralph Weissleder *
*Center for Molecular Imaging Research; yWellman Laboratories of Photomedicine, Massachusetts General
Hospital, Charlestown, MA 02129, USA
Abstract
The effect of intralysosomal proteolysis of near- infrared
fluorescent (NIRF ) self -quenched macromolecular
probe (PGC-Cy5.5) has been previously reported and
used for tumor imaging. Here we demonstrate that
proteolysis can be detected noninvasively in vivo at the
cellular level. A codetection of GFP fluorescence (using
two-photon excitation) and NIRF was performed in
tumor-bearing animals injected with PGC-Cy5.5. In vivo
microscopy of tumor cells in subdermal tissue layers
(up to 160 m) showed a strong Cy5.5 dequenching
effect in GFP-negative cells. This observation was
corroborated by flow cytometry, sorting, and reverse
transcription polymerase chain reaction analysis of
tumor- isolated cells. Both GFP-positive (81% total )
and GFP-negative (19% total ) populations contained
Cy5.5 -positive cells. The GFP-negative cells were
confirmed to be host mouse cells by the absence of rat
cathepsin mRNA signal. The subfraction of GFP-
negative cells (2.5–3.0%) had seven times higher NIRF
intensity than the majority of GFP-positive or GFP-
negative cells (372 and 55 AU, respectively). Highly
NIRF-positive, FP-negative cells were CD45- and
MAC3-positive. Our results indicate that: 1) intracellular
proteolysis can be imaged in vivo at the cellular level
using cathepsin-sensitive probes; 2) tumor-recruited
cells of hematopoetic origin participate most actively in
uptake and degradation of long-circulating macromo-
lecular probes.
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Introduction
In vivo optical imaging techniques are increasingly used to
study tumor microenvironment noninvasively using either
endogenous expression of fluorescent proteins [2-5], bio-
luminescence [6], or intravenously administered fluorescent
reporters [7-10]. Whereas the vast majority of studies have
been done using intravital microscopy, more recently,
macroscopic imaging techniques have become available to
noninvasively study tumors or detect them in a clinical setting
[11,12]. Irrespective of the mode of specific signal detection
(absorption [13,14] or fluorescence), it has become clear
that reporter probes could play an important role in extending
the capabilities of optical imaging.
Optical imaging in living animals and humans dictates the
use of near - infrared fluorochromes. The use of near- infrared
fluorescence (NIRF) reporters in vivo has an inherent
advantage in that: 1) tissues and blood have a high
transmittance in the near- infrared range (700–850 nm) as
opposed to the visible light; and 2) lower interference of
scattered excitation far - red light. As a result, the fluores-
cence signal excited in the deeper layers of tissue than in the
case of visible light fluorescence can potentially be acquired
(reviewed in Ref. [11] ). A number of nonspecific [9 ],
targeted [15-17], and enzyme-activatable reporter probes
[1,18-20] have previously been developed for cancer
imaging. The observation that fluorochromes can be effi-
ciently quenched and dequenched is the underpinning
principle of mRNA-sensing beacons [21,22] and peptide-
based protease reporter probes [19,20]. Our laboratory has
been interested in the synthesis and application of a number
of protease-specific imaging probes. One lead compound
with high likelihood of clinical development is a cathepsin B–
sensing NIRF probe [1]. This NIRF probe was originally
designed using a biocompatible protected graft copolymer
(PGC), which had been tested clinically [23]. The PGC has a
long circulation time, resulting in accumulation in tumors
[24,25] while being nonimmunogenic [26].
The prototype probe has been used to detect early breast
tumors [27] and, more recently, gastrointestinal tumors [28].
The probes have been shown to unequivocally improve the
detection of tumors and facilitate detection of early dysplastic
lesions [28]. Cathepsin B is involved in several key
processes of tumor progression including 1) extracellular
matrix remodeling [29,30]; 2) invasion and metastasis
[31,32]; and 3) in vivo tumor cell endocytosis [1 ]. Therefore,
we decided to further identify the cell types that participate
in enzymatic dequenching of fluorescence of cathepsin
B–specific probes. In particular, the contributions of tumor
cells and host stromal cells to probe activation had not been
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investigated, yet form a critical part in understanding how the
self -quenched probes work in vivo. We used confocal
intravital microscopy to visualize proteolytic activity in 9L
tumor cells constitutively expressing green fluorescent
protein (GFP) and host -derived (GFP-negative) cells to
differentiate the roles of tumor and tumor-recruited cells in
the effect of NIRF dequenching.
Materials and Methods
Synthesis of PGC-Cy5.5
Macromolecular probe, a graft copolymer of poly-L - lysine
and methoxy polyethylene glycol, was prepared as
described in Ref. [25] with modifications. Methoxy poly-
ethylene glycol succinate (molecular weight 5 kDa; Shear-
water Polymers, Birmingham, AL) was covalently attached
to poly-L- lysine (15–35.5 kDa) using activation with water -
soluble carbodiimide in the presence of sulfosuccinimide
(Pierce, Rockford, IL) as described in Ref. [25]. Under
chosen conditions, this synthetic step results in a 25%
modification of free amino groups. The graft copolymer was
purified from the excess of MPEGs using ultrafiltration on
UFP cartridge with a cut -off of 100 kDa (A/G Technology,
Framingham, MA). The graft copolymer was then further
modified with the monoreactive Cy5.5 N -hydroxysuccini-
mide ester (Amersham-Pharmacia Biotech, Piscataway,
NJ) as in Ref. [1 ]. Briefly, 1 mg of PGC was dissolved in 200
l of 0.05 M NaHCO3, pH 8.7, and added to dried contents of
Cy5.5 NHS modification vial (Amersham-Pharmacia Bio-
tech). This amount of Cy5.5 dye, formulated by the
manufacturer for antibody modification, resulted in desirable
modification yield. Three hours later, PGC-Cy5.5 probe was
purified by two sequential spins on BioGel P30 minicolumns
(Bio-Rad, Hercules, CA) saturated with BSA and equili-
brated with sterile phosphate-buffered saline (PBS). The
amount of Cy5.5 attached to PGC and/or injected intra-
venously was verified using spectrophotometry at 675 nm,
assuming e=250,000 M1 cm1. Control preparation of
PGC (noncleavable) was prepared using poly-D- lysine and
MPEG-SPA attached to N -e - lysine groups through non-
cleavable bonds (Shearwater Polymers). Dequenching of
the probe was tested by measuring fluorescence increase
(ex 675/em 694) in a mixture containing 10 g of PGC-
Cy5.5 and 100 U of trypsin (10 g) in 1 ml of PBS, pH 7.0, at
378C. In some experiments, bovine pancreatic trypsin
inhibitor (200 U) was added to the polymer to test enzyme
specificity. HPLC analysis of PGC-Cy5.5 was performed
using SEC-5 (Rainin Instruments, Woburn, MA) gel
permeation column eluted with 0.05 M sodium phosphate,
pH 6.8.
Cell Culture
Stably transfected rat gliosarcoma 9L-GFP-34-1 line
[3,33] was propagated in Dulbecco’s modified Eagle’s
medium (DMEM; Cellgro; Mediatech, Washington, DC),
with 10% FBS and 1% penicillin /streptomycin (Cellgro;
Mediatech) and 1 mg/ml G418 (Sigma, St. Louis, MO).
Animal Model Female nu/nu mice (MGH Radiation Oncol-
ogy breeding facilities, n=10, total of five independent
experiments) were anesthesized using ketamine (80 mg/
kg) and xylazine (12 mg/kg). 2105 cells in 25 l of serum-
free cell culture medium were injected subcutaneously into
posterior aspect of the ear pinna. Tumors reached the size of
3 to 4 mm in diameter on 10th to 14th day after the
inoculation. Animals were injected with 0.25 mg of PGC-
Cy5.5 (200 nmol of Cy5.5/kg) intravenously in a volume of
100 l of PBS. In 6 or 12 hours postinjection, animals were
anesthesized and subjected to imaging as described below.
Near- Infrared Imaging
Optical reflectance imaging was performed using a
previously described system [18]. The imaging set -up
consisted of a light - tight box equipped with a 150-W halogen
lamp and an excitation filter set suitable for Cy5.5 excitation
(610–650 nm; Omega Optical, Brattleboro, VT). Excitation
light was homogeneously distributed over the field of view
(FOV) using light diffusers. Fluorescence was detected by a
12-bit monochrome CCD camera (Kodak, Rochester, NY)
equipped with a f /1.2 12.5- to 75-mm zoom lens and an
emission 700-nm longpass filter (Omega Optical ). The
animals were imaged in supine position with tumors facing
the glass surface. Images were digitally acquired as TIFF
files and processed using commercially available software
( IP Lab Spectrum; Signal Analytics, Vienna, VA).
Confocal and Two-Photon Imaging Set-Up
Confocal and two-photon imaging set-up consisted of a
scanning laser microscope with a spinning polygon for the
fast scanning axis and a galvanometer-mounted mirror for
the slow axis [34]. A mode- locked titanium:sapphire laser
(Coherent Mira, 100 mW at 820 nm) was used for two-
photon excitation of the GFP, and a HeNe laser (17 mW at
633 nm, Model 1144P; Uniphase, San Jose, CA) was used
for excitation of the Cy5.5 probe. The laser beam was
focused to a diffraction- limited spot at the sample using a
30, 0.9 NA water immersion objective lens (LOMO Optics,
Germantown, MD). The FOV was 400300 m. The
fluorescence photons were collected by the same objective
lens, and spectrally separated by a dichroic filter. The green
( two-photon-excited) fluorescence was detected with a
photomultiplier tube (Hamamatsu Model HC-124-2) without
descanning. The red (one-photon-excited) fluorescence
was descanned and separated from the excitation by a
bandpass filter (Omega XF 3076) and detected by an
avalanche photodiode (Hamamatsu Model C5460). Both
scanning and image acquisition were computer -controlled
(National Instruments 1408 and Scion Image VG-5) to
produce variable frame rates from 5 to 30 Hz. Additional
frame averaging was performed by using NIH Image
software to increase sensitivity. The animals were anesthe-
sized using ketamine–xylazine mixture and imaged in
supine position with ear tumors facing a glass coverslip
placed over the water immersion objective. The contact
between the skin and glass was achieved by applying a gel
with a refractive index of 1.34 onto a skin surface. First, the
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skin surface was identified using reflectance mode imaging.
Next, the GFP-positive tumor cells were imaged in the two-
photon (green) channel. Optical sections were acquired in
15- to 20-m steps down to 150 to 200 m from the skin
surface, using an objective lens mounted on a micrometer -
driven stage. After this stage, the titanium:sapphire laser was
blocked, the HeNe excitation beam was unblocked, and the
one-photon fluorescence (red channel) was acquired. The
depth and the FOV were kept the same for the one- and
two-photon scans in order to facilitate image analysis.
Fluorescence coregistration within the same optical section
was verified using a cell culture sample prepared using
WTK1 lymphoblast cells stained with DiD (plasma mem-
brane) and monobromobimane, a GSH-sensitive probe
(cytoplasm). DiD fluorescence (red) was excited with one
photon at 633 nm and monobromobimane fluorescence
(green) was excited in a two-photon mode at 800 nm.
Flow Cytometry and Fluorescence Microscopy
Tumor cells were isolated from excised tumors using
collagenase/hyaluronidase digestion. Briefly, tumors were
minced in small (1–2 mm) fragments and treated with
collagenase (1800 U/ml) and hyaluronidase (1220 U/ml) in
Hank’s solution containing 20 g/ml DNAse I and 2 mM
MgCl2, pH 7.0, for 30minutes at 378C. Tissue fragments were
disaggregated using pipetting. Isolated cells were washed by
passing through a 2-ml step of 40% Histopaque-1077 in
HBSS by sedimenting at 1000g for 10 minutes. Cells were
washed again in HBSS (800g, 10min) and kept on ice before
sorting. After blocking with 1% BSA in PBS, cells were
incubated in the presence of Fc block (anti–CD16/CD32
dilution 1:50; Pharmingen, San Diego, CA) and one of the
following rat monoclonal antibodies: anti -CD45, anti -CD31
(PECAM-1), anti–VCAM-1, anti -MAC3 (Pharmingen) dilu-
ted 1:100, washed and incubated with phycoerythrin- labeled
anti–rat IgG (Pharmingen) (dilution 1:50). Flow cytometry
(FACSCalibur; Beckton Dickinson, San Jose, CA) was
performed using samples with or without the first antibody.
Sorting of nonfixed cell isolates into GFP-negative and
GFP-positive subfractions was performed using Becton
Dickinson fluorescence-activated sorter. Isolated fractions
were immediately processed for RNA isolation and reverse
transcription polymerase chain reaction (RT-PCR). Fluo-
rescence microscopy was performed using an inverted
microscope (Zeiss Axiovert 100 TV, Wetzlar, Germany)
fitted with a XF-100 ( fluorescein) and XF48 (near - infrared)
filter sets (Omega Optical ). Images were acquired using a
Photometrics CH250 CCD (Photometrics, Tucson, AZ) with
image acquisition and storage controlled by IP Lab Spectrum
software (Signal Analytics).
RT-PCR Analysis
Total RNA was isolated from 0.75105 to 1105 cells
using the Absolutely RNA RT-PCR Miniprep Kit (Strata-
gene, LaJolla, CA) according to manufacturer’s recommen-
dations. RT-PCR was performed using Titan One Tube
RT-PCR Kit (Roche, Mannheim, Germany). Ten nano-
grams of total RNA was used for one reaction. The cDNA
preparations obtained using RNA templates isolated from
nonfluorescent and fluorescent cells were subjected to PCR
analysis for cathepsin B and cathepsin H mRNA expression
using primers allowing to account for allogenicity ( i.e., to
differentiate between host and tumor xenograft ). The
following four pairs of cathepsin-specific primers were used:
1) mouse cathepsin B 50–GGAAGGGTTGCGTTCGGT-
GAGG; 30–GCAGGTTCGGTCAGAAATGGC; 2) mouse
cathepsin H* 50–AGCTCGGTGGAGTACAACC; 30–GCAA-
CAGCTTT TTGGGGGTTGAATC; 3) rat cathepsin B* 50–
GGAAAGGG TTGGGTTCAGCG; 30 -GCAGATTCGGTCA-
GACATG; 4) rat cathepsin H 50–CGAGGGAGTACAGCCA-
CAGG; 30–CGCG ACGGCCTTTTCTGGGTTGAATTTGC.
Beta-actin specific primers were used to account for overall
levels of mRNA expression and to normalize PCR signals.
Primers indicated by an asterisk are 100% species-specific.
RT-PCR for beta-actin, mouse and rat cathepsin H, and rat
cathepsinBwereperformedat thefollowingconditions:508C–
30 minutes, 1 cycle; 948C–3 minutes, 1 cycle; 948C–30
seconds, 658C–45 seconds, 30 cycles; 698C–1 minute,
698C–10minutes, 1 cycle. Annealing temperature for mouse
cathepsinBinthereactionwaschangedto678C.PCRproducts
were analyzed by agarose electrophoresis; results were
digitized using Kodak CD40 camera (as 16-bit TIFF) and
analyzedusingIPLabSpectrumsoftware.
Enzymatic Activity Assay
Tree hundred thousand cells were lysed in 30 l of 1%
Triton X-100, 10 mM DTT, 10 mM potassium acetate, pH
6.0, for 10 minutes and the lysate was added directly to a
cuvette containing 460 l of 0.4 mM N -Cbz–Arg–Arg–7-
amino-4-methylcoumarin (Bachem AG, Bubendorf, Swit-
zerland), 0.1 M potassium acetate, 0.05 M NaCl, 20 mM
Mes, 1 mM EDTA, pH 6.0. Kinetics of product release (7-
amino-4-methylcoumarin) was acquired at ex 320 nm/em
420 nm. The enzyme activity was determined using initial
reaction rate values and converted into enzymatic activity
units using cathepsin B (343 U/mg; CN Biosciences, La
Jolla, CA) as a standard.
Image Analysis
Eight- or 16-bit TIFF images obtained using a CCD were
subjected to segmentation for determining coregistration of
GFP and NIRF signal in the same cells within a single
confocal slice. Green fluorescence images (GFP fluores-
cence) were segmented using IP Lab Spectrum software
using segment area limitations to account for single cells
only. The obtained segment layer was overlaid over a
corresponding NIRF image. Fluorescence within segments
was then measured and distribution of fluorescence in 10
individual cells was plotted as a histogram.
Results
PGC-Cy5.5 Dequenching In Vitro
Initially, PGC-Cy5.5 probe cleavage was tested in vitro
to determine the degree of self -quenching and the ability
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of proteases to release the fluorescence due to the
enzymatic cleavage of the lysine-containing backbone
polymer. For PGC-Cy5.5 used in the study, NIRF
increased 35 to 40 times after the treatment with trypsin,
a model serine protease capable of degrading poly- lysine,
or dithiotreitol -activated cathepsin B. The NIRF increase
was blocked by 96% to 97% in the presence of specific
enzyme inhibitors. Size exclusion HPLC analysis showed a
time-dependent decrease of high-molecular-weight PGC-
Cy5.5 peak in the presence of trypsin. Control PGC-Cy5.5
with a poly-D- lysine backbone was not cleavable by
trypsin or cathepsin B.
Imaging of PGC-Cy5.5 Cleavage in Tumor Xenografts
Animals injected subdermally in the ear with 9L-GFP
tumor cells developed 3- to 4-mm tumors within 10 days.
Mice received an intravenous injection of self -quenched
Cy5.5- labeled PGC probe at 6 or 12 hours prior to imaging.
Animals were subjected to macroscopic NIR and GFP
fluorescence imaging [18] to colocalize tumor-specific
GFP marker expression and NIR fluorescent probe
dequenching (Figure 1 ). All ectopic 9L-GFP tumors showed
a strong GFP expression. Dequenching of PGC-Cy5.5
probe was most prominent in larger tumors (with a diameter
of 3–4 mm) at 12 hours after injection. Tumor/background
signal ratio measured using region-of - interest fluorescence
intensity measurements varied between 3 and 4. At the
earlier time point (6 hours postinjection), measured NIRF
signal never exceeded 1.5- fold over the background signal
measured in areas where tumor was absent. Fluorescence
was nearly absent in small poorly vascularized tumor
nodules within the same ear (Figure 1 ). Histological
examination of excised tumors showed no extensive
necrosis.
In Vivo Microscopy
Animals with verified NIRF dequenching were subjected
to a transdermal confocal two-photon microscopy using a
set-up described in Materials and Methods. In preliminary
experiments, a double-stained preparation of cells (WTK1
cells stained with DiD and monobromobimane; Figure 2 )
was used to verify colocalization of fluorescence using
single-photon and double-photon excitation modes in the
same optical section. The overlapped image (Figure 2,
image C) demonstrated a high degree of coincidence of
one- and two-photon fluorescence signals within the same
optical section.
In vivo, using a double-channel fluorescence registration,
the dequenching of PGC-Cy5.5 could be observed individ-
ually in populations of tumor and tumor accessory cells
because only gliosarcoma cell cytoplasm fluorescence was
excitable in two-photon mode. Both green fluorescent
(Figure 3; arrow ) and GFP accessory cells demonstrated
NIRF dequenching corresponding to cellular endocytotic
compartment (Figure 3 ). At all time points, no NIR
fluorescence was detectable within microvessels supplying
tumors. The imaging of tumor cells in subdermal tissue
layers showed that near- infrared signal was detectable at 6
hours postintravenous administration 20 to 100 m deep
from the skin surface. At 12 hours, NIR fluorescence
appeared significantly brighter and the dequenching could
be observed in deeper layers of tissue (up to 160 m).
Generally, at this time point, few GFP-positive cells had NIR
fluorescence. Merged images showed coregistration of both
fluorescent labels in some GFP-positive cells (arrow, yellow
signal ). The majority of cells showing the most prominent
NIR fluorescence ( i.e., dequenching of Cy5.5 label ) were
GFP-negative. Image segmentation analysis performed
using eight images obtained in three animals in two
independent experiments showed the presence of different
NIRF-positive cell populations in tumors including a low-
Figure 1. Macroscopic reflectance fluorescent imaging of 9L -GFP gliosar-
coma in mouse ear model. (A ) Visible light image. (B ) Expression of tumor
GFP marker protein in tumors. (C ) NIRF image demonstrating PGC-Cy5.5
probe cleavage. A total of three individual nodules are visible. Cy5.5
dequenching was observed in two larger tumors.
Neoplasia . Vol. 4, No. 3, 2002
Fluorescent Reporter Probe Bogdanov et al. 231
fluorescent cell population (73% of total GFP-positive cells;
fluorescence intensity <55 AU) and a high- fluorescent cell
population (7% of GFP positive cells; fluorescence intensity
>100 AU) (Figure 4 ).
Figure 3. Confocal in vivo microscopy of 9L -GFP tumor after PGC-Cy5.5 intravenous injection. The images are superimposed GFP fluorescence (green, two -
photon mode excitation ) and Cy5.5 NIRF ( red, single - photon excitation ). The images were acquired at the different depths (0–160 m from the skin surface )
shown in the lower right corner. The arrow points to GFP -positive cells showing a strong Cy5.5 NIRF signal ( yellow on superimposed image, 100 m).
Figure 2. The verification of one - and two -photon colocalization using an in vivo imaging system. WTK1 lymphoblast cells were stained with DiD (A, plasma
membrane ) and monobromobimane, a GSH-sensitive probe (B, cytoplasm ). DiD fluorescence ( red ) was excited with one photon at 633 nm and
monobromobimane fluorescence was excited with two photons at 800 nm. Image (C ) shows superimposed images (A ) and (B ).
232 Fluorescent Reporter Probe Bogdanov et al.
Neoplasia . Vol. 4, No. 3, 2002
Analysis of Isolated Tumor Cell Populations
To corroborate observations made using confocal micro-
scopy in subdermal tumor tissue layers with the whole tumor
cell FACS analysis, tumors were resected and individual
tumor cells were isolated using a collagenase/hyaluroni-
dase treatment. Fluorescence of isolated cells was then
analyzed using flow cytometry (Figure 5 ). Both green
fluorescent (81% total ) and nonfluorescent cells (19%
total ) were also fluorescent in the far - red wavelength range
(FL4 channel ). A subfraction of GFP-negative cells (2.5–
3%) showed a significantly higher NIRF intensity — 370
AU — compared to fluorescence intensity of 55 AU (CV
30–33%) measured in the majority of cells of GFP-positive
or GFP-negative cells (Figure 5 ). The fractions of GFP-
negative (mouse host ) and GFP-positive (rat gliosarcoma)
cells were isolated using fluorescence-activated sorting and
subjected to RT-PCR analysis for the purpose of: 1)
performing comparative analysis of cathepsin B and H
expression in these subfractions; and 2) determining
whether the GFP-negative and GFP-positive fractions
corresponded to mouse stromal and rat gliosarcoma cells.
The latter experiment can reveal a potential cross-contam-
ination and determine potential loss of GFP marker by rat
9L-GFP cells in vivo. An RT-PCR analysis using highly
species-specific primer set for rat cathepsin B showed the
absence of rat mRNA in GFP-negative cells (Figure
6; lanes1 and 2 ; Table 1). Mouse cathepsin B mRNA gave
a strong specific signal after the amplification (Table 1). The
ratio of PCR signals (normalized by  -actin signal ) for
cathepsin B in mouse cells to rat cathepsin B was equal to
3.5. To compare the expression levels of catalytically active
enzyme in both cell types, we performed enzyme activity
measurements using lysates prepared from FACS-sorted
cells and cathepsin B–specific substrate. The measured
enzyme activity in mouse was 3.6 times higher than in tumor
rat cells, suggesting a good correlation with RT-PCR data
(Table 1). Interestingly, cathepsin H mRNA expression was
higher in rat 9L cells than in the stromal mouse cells, and
the level of expression of this enzyme was higher in rat cells
than that of cathepsin B.
As determined by flow cytometry, cells with high NIRF
were CD45-positive and macrophage differentiation antigen
(MAC3)–positive, but VCAM-1– and CD31-negative
(Table 2). Microscopic examination of tumor- isolated cells
showed that with NIRF, dequenching activity was present in
both tumor cells and GFP-negative cells (Figure 7;A C ).
The cells with no detectable GFP fluorescence (Figure
7;A and B; arrow ) had large NIR fluorescent compartment
Figure 4. Confocal microscopy image analysis showing the distribution of
NIRF in GFP -positive cell population ( a total of 156 cells ) within a confocal
slice ( n=4 ). Fluorescence intensities were determined after image segmen-
tation and analysis as described in Materials and Methods.
Figure 5. Flow cytometry analysis of cells isolated from 9L -GFP tumors
(A,B ) obtained from animals injected with PGC-Cy5.5, 24 hours before cell
harvesting. (A ) A histogram showing fluorescence intensity of GFP -positive
and GFP-negative cell populations. (B ) Cy5 /GFP dot graph showing
subpopulations of highly positive cells in upper left ( shown in a square
window ) and right quadrants.
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and appeared significantly brighter than GFP-positive tumor
cells.
Discussion
Tumor-associated proteases have received much attention
as potential targets for therapeutic and imaging drugs within
tumor microenvironments. The role of proteases in tumor
progression, invasion, migration, angiogenesis, and meta-
stasis has been subjected to extensive research ( reviewed
in). Specifically, protease expression and resultant extrac-
ellular matrix remodeling are regulated by complex inter-
actions between extracellular matrix components and cells
populating the tumor, including mesenchymal and hema-
topoetic stromal cells [38]. Recent development of biocom-
patible, enzyme-specific reporter probes afforded in vivo
sensing of specific proteolytic activity useful for tumor
detection [1], transgene imaging [19], and efficacy testing
of MMP-2 inhibitors [20]. Detection of proteolytic activity
using PGC-enhanced fluorescent imaging allowed to differ-
entiate between normal and neoplastic tissue in vivo
[1,18,39]. The explanation of underlying phenomenon is in
the sequence of events preceding catalytic release of NIRF
self -quenched fluorophores. Tumor vessels supplying pro-
liferating neoplastic tissue with nutrients are known to have
much higher endothelial permeability than normal blood
vessels [40-42]. Furthermore, tumor interstitial volume is
higher than in normal tissues [43,44]. These factors act
synergistically, resulting in a ‘‘passive’’ accumulation of graft
copolymers in tumors [24,45]. The tumoral accumulation
(3–5% of injected dose per gram of tissue [45] ) is, in part,
due to the ability of macromolecules to circulate for long
periods of time (T1 / 2=20–30 hours [26] ) and resultant
persistence of concentration gradient across tumor endo-
thelium. Cells comprising the tumor mass subsequently
internalize a fraction of PGC-Cy5.5 that accumulated in the
interstitial compartment. Tumor cells are capable of active
pinocytosis of a variety of macromolecules and colloids in
vivo and in vitro [46,47]. For example, we previously
reported the effect of tumor cell endocytosis of dextran-
coated iron oxide nanoparticles that are internalized in tumor
cells through fluid uptake pathway [48]. However, tumors
harbor numerous tumor-recruited and stromal cells supply-
ing the tumor with growth factors and participating in
extracellular matrix remodeling (reviewed in Ref. [49–51] ).
Figure 6. NIRF microscopy of cells isolated from 9L -GFP tumors. (A ) GFP. (B ) NIRF. (C ) Merged images. A GFP -negative, highly NIRF -positive cell with a large
NIRF intracellular compartment is indicated by an arrow.
Table 1. Analysis of Cathepsin B and H Expression in Cells Isolated from 9L -GFP Tumor Xenograft.*
Cell Type Primer Specificity Amplified Fragment
Size ( bp )
Normalized
Signal Intensity
Specific Cathepsin
B Activity (U /ml cells )*
GFP -positive Rat cathepsin B 162 101.8 0.015
Rat cathepsin H 529 143.5
Mouse cathepsin B** 160 117.2
Mouse cathepsin H 532 14.1
GFP -negative Rat cathepsin B 162 5.8 0.058
Rat cathepsin H 529 7.6
Mouse cathepsin B** 160 354.3
Mouse cathepsin H 532 44.8
*Specific activity was determined using a fluorescent substrate as described in Materials and Methods.**Primers specific for mouse cathepsin B are not
species - specific.
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Monocytes, resident macrophages, and dendritic cells
that may infiltrate the tumor may exhibit a very high level of
solute internalization due to macropinocytosis [52,53]. Due
to a high proteolytic activity in endocytotic compartment of
phagocytic cells, the input of these cells in the total tumoral
solute uptake can be substantial. The propensity of growing
tumors to attract nontumor cells may vary considerably and
depends on local secretion of chemokines [54] as well as on
the tumor cell apoptosis rate. Therefore, we set forth to
investigate whether tumor- recruited cells might have a role
in previously observed NIRF dequenching in vivo [1 ]. A
recently described multiphoton intravital laser scanning
microscopy (MPLSM) [55] is a powerful in vivo technique
allowing for real - time imaging of cells in vivo in natural
microenvironment. In our work, we used a similar approach.
A custom-built microscopy set-up allowed confocal and
two-photon fluorescence microscopy of tumor cells using a
direct transdermal illumination of the tumor. A significant
advantage of the system is in that it does not require any
additional tissue perturbation (e.g., glass window implanta-
tion). With high resolution, we successfully imaged tumor
cells proliferating in subdermal tissue layers (20–160 m
deep from the skin surface; Figure 3 ). Remarkably, these
imaging experiments suggested that the strongest NIRF
signal resulting from Cy5.5 dequenching originated in GFP-
negative cells (Figures 3 5 ). The validity of this observa-
tion was tested using flow cytometry of cell preparations
isolated from tumors. Flow cytometry showed that both
GFP-positive and GFP-negative populations contained
predominantly Cy5.5-positive cells (Figure 5 ). However, a
minor fraction of GFP-negative cells (2.5–3.0% total )
showed a seven- times-higher fluorescence intensity than
the majority of GFP-positive or GFP-negative cells. This
observation confirms microscopy data indicating that GFP-
negative subpopulation of cells contains a higher fraction of
cells that degrade PGC-Cy5.5 and release NIR fluorescent
signal if compared to GFP-positive tumor cells. The fraction
of GFP-negative cells consisted almost exclusively of host
(mouse) cells, which was proven by RT-PCR analysis using
primers specific for rat or mouse cathepsin mRNA (Figure 6 ,
Table 1). Direct measurement of enzymatic activity in GFP-
negative cells and GFP-positive 9L cells sorted from tumor
tissue also indicated that enzymatic activity of cathepsin B
was higher in stromal cells than in gliosarcoma cell
population (Table 1). The majority of highly NIRF-positive,
GFP-negative cells were CD45- and MAC3-positive (Table
2) and contained brightly fluorescent intracellular vesicles
(Figure 7 ), suggesting that optical imaging probe was
actively degraded by monocyte/macrophage/dendritic cell
populations residing in the tumor.
In conclusion, we demonstrated that noninvasive confocal
and two-photon microscopy could be used as imaging
modality for investigating physiology of peripherally located
tumors at the cellular level in intact animals. Our data
indicate that tumor-associated proteolysis can be imaged in
vivo on the cellular level during tumor progression. The
further progress in novel probe design would allow elucida-
tion of the role of individual cell populations in tumor growth
as well as the function of cellular proteases during cancer
progression.
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